The global in situ hybridization market is witnessing steady growth, driven by the increasing adoption of this laboratory technique in molecular diagnostics and research applications. The ability to precisely localize specific segments of nucleic acid within histologic sections has led to its widespread use in studying gene expression patterns and identifying genetic abnormalities in various diseases, including cancer. The market is propelled by advancements in probe technologies and automation, facilitating efficient and accurate analyses. With growing demand from the healthcare and life sciences sectors, the global in situ hybridization market is expected to continue its upward trajectory.
According to Data Bridge Market Research, the Global In Situ Hybridization Market was USD 1,003.50 million in 2022, would rocket up to USD 2,397.27 million by 2030 and is expected to undergo a CAGR of 11.5% during the forecast period of 2023-2030.
“Prevalence of cancer facilitates market growth”
The prevalence of cancer serves as a significant driver of the global in situ hybridization market. As cancer remains a leading cause of morbidity and mortality worldwide, there is an increasing demand for advanced diagnostic tools to aid in early detection and accurate characterization of tumors. In situ hybridization techniques offer valuable insights into gene expression patterns and molecular alterations within cancer cells, enabling clinicians to tailor personalized treatment approaches. The rising burden of cancer cases globally fuels the adoption of in situ hybridization technologies, driving market growth in the field of molecular diagnostics.
What restraints the growth of global in situ hybridization market?
“Availability of alternative methods for gene expression analysis”
One significant restraint of the global in situ hybridization market is the availability of alternative methods for gene expression analysis and the complications associated with existing application technologies. As advancements occur in the field of molecular diagnostics and gene expression profiling, researchers and clinicians may opt for alternative techniques that offer comparable or enhanced results. Additionally, the complexities and limitations of current in situ hybridization applications, such as technical challenges and variability in results, can hinder its widespread adoption, impacting the overall market growth for this technology.
Segmentation: Global In Situ Hybridization Market
The situ hybridization market is segmented on the basis of technology, application, end user, type and product.
- On the basis of technology, the situ hybridization market is segmented into chromogenic in situ hybridization (CISH), fluorescence in situ hybridization (FISH).
- On the basis of application, the situ hybridization market is segmented into immunology, microbiology, cancer diagnostic, neuroscience and infectious diseases..
- On the basis of end user, the situ hybridization market is segmented into biotechnology/pharmaceutical companies, academic and research institutes, molecular diagnostic labs.
- On the basis of type, the situ hybridization market is segmented into DNA, RNA.
- On the basis of product, the situ hybridization market is segmented into instruments, probes and kits.
Regional Insights: North America dominates the Global In Situ Hybridization Market
North America's dominance in the in situ hybridization market is attributed to the rising incidence of cancer and infectious diseases in the region. As healthcare providers and researchers focus on early detection and accurate diagnosis, the demand for in situ hybridization techniques has increased. The region's advanced healthcare infrastructure and strong R&D capabilities also contribute to its leading position in adopting and implementing these innovative molecular diagnostic methods.
Asia-Pacific (APAC) is poised for significant growth in the in situ hybridization market from 2022 to 2029, driven by a surge in research and development investments. APAC countries are increasingly investing in healthcare advancements, bolstering their capabilities in genetic research and molecular diagnostics. As the region witnesses a growing emphasis on precision medicine and personalized treatments, the demand for in situ hybridization technologies is expected to rise, propelling market expansion..
To know more about the study visit, https://www.databridgemarketresearch.com/de/reports/global-in-situ-hybridization-market
Recent Developments in Global In Situ Hybridization Market
- October 2021, Leica Biosystems launched the RNAscope VS Universal HRP Reagent Kit, designed to enhance ISH assay sensitivity for detecting low-abundance RNA targets with high specificity.
- June 2021, Bio-Techne acquired Asuragen, a leader in molecular diagnostics and RNA-based technologies, strengthening its capabilities in RNA-based diagnostics, including ISH.
- March 2021, PerkinElmer introduced the Vectra Polaris II Automated Quantitative Pathology Imaging System, enabling researchers to visualize and quantify multiple biomarkers in tissue samples using multiplexed IHC and ISH.
- October 2020, Agilent Technologies unveiled the GenetiSure Pre-Screen Kit, streamlining ISH-based pre-screening of clinical samples for copy number variations in cytogenetic laboratories.
The Prominent Key Players Operating in the Global In Situ Hybridization Market Include:
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Danaher (U.S.), BioGenex (U.S.)
- Advanced Cell Diagnostics, Inc. (U.S.)
- Bio SB (U.S.)
- Leica Biosystems Nussloch GmbH (Germany)
- Oxford Gene Technology (U.K.)
- Medtronic (Ireland)
- GENERAL ELECTRIC (U.S.)
- Siemens (Germany)
- Koninklijke Philips N.V. (Netherlands)
- IMRIS (Canada)
- NeuroLogica Corp. (U.S.)
- Ziehm Imaging GmbH (Germany)
Above are the key players covered in the report, to know about more and exhaustive list of global in situ hybridization market companies contact, https://www.databridgemarketresearch.com/de/contact
Research Methodology: Global In Situ Hybridization Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
